Discussing Risankizumb, Differences in IL-23 Inhibitor Epito

Discussing Risankizumb, Differences in IL-23 Inhibitor Epitopes with Christopher Bunick, MD, PhD

This interview with Bunick featured a discussion of his team’s recent data comparing anti-IL-23 biologics, epitopes, and comparisons with risankizumab.

Related Keywords

Christopher Bunick , Yale School Of Medicine , Structural Basis , Long Term Efficacy , Yale School , Psoriasis , Skyrizi , Epitope , Risankizumab , Guselkumab , Il 23 ,